Endobronchial coil therapy in severe emphysema: 6-month outcomes from a Swiss National Registry.

Fellrath, Jean-Marc; Scherer, Thomas; Franzen, Daniel P; Lovis, Alban; von Garnier, Christophe; Plojoux, Jérôme; Soccal, Paola M (2018). Endobronchial coil therapy in severe emphysema: 6-month outcomes from a Swiss National Registry. Journal of thoracic disease, 10(Suppl 23), S2711-S2718. Pioneer Bioscience Publishing 10.21037/jtd.2018.04.53

[img] Text
jtd-10-S23-S2711.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (213kB) | Request a copy

Background

Endobronchial coils have been demonstrated in three randomized, controlled trials to improve quality of life, exercise tolerance, and lung function in patients with severe emphysema. This therapy is CE-marked and commercially available in Switzerland. Coil treated patients are followed in a post-market Swiss registry to collect safety and effectiveness data in routine clinical practice.

Methods

The Swiss coil registry was initiated in October 2013. At the end of November 2016, an interim analysis of all 64 patients treated in five centers was performed to evaluate safety and effectiveness at six months post treatment.

Results

patients had completed bilateral treatment with 6-month follow up at the time of data analysis. Patients had very severe, symptomatic emphysema and hyperinflation [38% male, mean age 66 years, BMI 24, FEV1 30% pred., residual volume (RV) 247% pred., 6-minute walking distance (6-MWD) 272 m, St. George Respiratory Questionnaire (SGRQ) 57 points]. Up to 6 months following treatment, seven serious adverse events (SAE) were reported in 6/29 patients. No device removals were necessary. At 6 months, responder rates [% achieving the minimal clinically important difference (MCID)] were as follows: RV (-0.35 L) 76%; FEV1 (+10%) 57%; SGRQ (-4 points) 87%; 6MWD (+26 m) 60%.

Conclusions

Endobronchial coil therapy performed in expert centers in Switzerland yields high 6-month responder rates across all relevant outcome.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Pneumologie (Erwachsene)
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology

UniBE Contributor:

von Garnier, Christophe

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2072-1439

Publisher:

Pioneer Bioscience Publishing

Language:

English

Submitter:

Rahel Holderegger

Date Deposited:

31 Jan 2019 15:15

Last Modified:

05 Dec 2022 15:24

Publisher DOI:

10.21037/jtd.2018.04.53

PubMed ID:

30210823

Uncontrolled Keywords:

Chronic obstructive pulmonary disease (COPD) bronchoscopic lung volume reduction coils emphysema registry

BORIS DOI:

10.7892/boris.123140

URI:

https://boris.unibe.ch/id/eprint/123140

Actions (login required)

Edit item Edit item
Provide Feedback